Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells

Qu, Xueping; Zhuang, Guanglei; Yu, Lanlan; Meng, Gloria; Ferrara, Napoleone

doi:10.1074/jbc.m111.326801

Cited by 80 publications

(68 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44,45 G-CSF is also a potent inducer of PROK2-expression in vitro and in vivo through STAT3 signaling. 42,46,47 However, neither IL6 nor IL10 triggers the expression of PROK2, 46 suggesting that these interleukins do not stimulate PROK2-expression following GR, which is consistent with our findings of increased IL6 expression (Fig. 2A).…”

Section: Methodssupporting

confidence: 90%

The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo

et al. 2013

View full text Add to dashboard Cite

Section: Methodssupporting

confidence: 90%

The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo

et al. 2013

View full text Add to dashboard Cite

“…Interestingly, Th17 cells produce the cytokine IL17, whose role in promoting tumor resistance to antiangiogenic therapy has begun to unravel recently (36). In addition, multiple myeloid-derived inflammatory mediators have been shown to mediate resistance to anti-VEGF therapy in preclinical models (36)(37)(38). Understanding how everolimus regulates OPN in these specific cell populations, and the consequences of intracellular versus soluble OPN (39), is of great interest.…”

Section: Discussionmentioning

confidence: 99%

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

Liu

Starr

Brady

et al. 2015

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

A novel combination of bevacizumab and everolimus was evaluated in refractory colorectal cancer patients in a phase II trial. In this retrospective analysis, plasma samples from 49 patients were tested for over 40 biomarkers at baseline and after one or two cycles of drug administration. Analyte levels at baseline and change on-treatment were correlated with progression-free survival (PFS) and overall survival (OS) using univariate Cox proportional hazard modeling. Multivariable analyses were conducted using Cox modeling. Significant changes in multiple markers were observed following bevacizumab and everolimus treatment. Baseline levels of six markers significantly correlated with PFS and OS, including CRP, Gro-a, IGFBP-1, TF, ICAM-1, and TSP-2 (P < 0.05). At C2D1, changes of IGFBP-3, TGFb-R3, and IGFBP-2 correlated with PFS and OS. Prognostic models were developed for OS and PFS (P ¼ 0.0002 and 0.004, respectively). The baseline model for OS consisted of CRP, Gro-a, and TF, while the on-treatment model at C2D1 included IGFBP-2, IGFBP-3, and TGFb-R3. These data demonstrated that multiple biomarkers were significantly modulated in response to bevacizumab and everolimus. Several markers correlated with both PFS and OS. Interestingly, these markers are known to be associated with inflammation and IGF signaling, key modulators of mTOR biology.

show abstract

“…This effect of G-CSF is mediated through recruitment of CD11b + Gr1 + MDSCs and increased number of endothelial progenitor cells [279]. The pro-angiogenic effects of MDSCs is in part driven by Bv8 (prokineticin 2/PK2), which is upregulated by G-CSF [282,283] through a STAT3 dependent mechanism [284]. G-CSF may further contribute to tumor angiogenesis by inducing VEGF-A production in neutrophils [285].…”

Section: Neutrophils At the Primary Tumor Sitementioning

confidence: 99%

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Sionov

Fridlender

Granot

2014

Cancer Microenvironment

342

261

View full text Add to dashboard Cite

Neutrophils are myeloid cells that constitute 50-70 % of all white blood cells in the human circulation. Traditionally, neutrophils are viewed as the first line of defense against infections and as a major component of the inflammatory process. In addition, accumulating evidence suggest that neutrophils may also play a key role in multiple aspects of cancer biology. The possible involvement of neutrophils in cancer prevention and promotion was already suggested more than half a century ago, however, despite being the major component of the immune system, their contribution has often been overshadowed by other immune components such as lymphocytes and macrophages. Neutrophils seem to have conflicting functions in cancer and can be classified into anti-tumor (N1) and pro-tumor (N2) sub-populations. The aim of this review is to discuss the varying nature of neutrophil function in the cancer microenvironment with a specific emphasis on the mechanisms that regulate neutrophil mobilization, recruitment and activation.

show abstract

Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells

Cited by 80 publications

References 47 publications

The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo

The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo

Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus

The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment

Contact Info

Product

Resources

About